特此公告。 长江医药控股股份有限公司董事会 证券代码：300391 证券简称：*ST 长药 公告编号：2025-082 长江医药控股股份有限公司 2025 年半年度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 2025年8月22日，长江医药控股股份有限公司（以下简称"公司"）召开第六 届董事会第二次会议，审议通过了公司2025年半年度报告及摘要。为使投资者全 面了解公司的经营成果、财务状况等，公司2025年半年度报告及摘要于2025年8月 26日在中国证监会指定信息披露网站巨潮资讯网上披露，敬请投资者注意查阅。 2025年8月26日 ...

证券代码：300391 证券简称：*ST 长药 公告编号：2025-079 长江医药控股股份有限公司 第六届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 一、董事会会议召开情况 长江医药控股股份有限公司（以下简称"公司"）第六届董事会第二次会议于 2025年8月22日现场加通讯表决方式在公司会议室召开，会议通知已于2025年8月12 日以电子邮件方式送达。本次会议由王波先生主持，应参与表决董事9人，实际参 与表决董事9人，其中翁浩先生、高应会先生、顾紫光先生、韩庆凯先生以通讯方 式出席并表决。本次会议为董事会定期会议，召集、召开的程序、方式符合有关法 律、行政法规、部门规章、规范性文件和公司章程规定。 二、董事会会议审议情况 1、关于2025年第一季度财务报告会计差错更正的议案； 本议案经公司董事会审计委员会、独立董事专门会议审议通过。 详情参见与本公告同日披露于巨潮资讯网的《关于2025年第一季度财务报告会 计差错更正的公告》、《2025年第一季度报告（更正后）》。 表决情况：赞成：9票；反对：0票；弃权：0票 表决结果：通过。 ...

长江医药控股股份有限公司 2025 年半年度报告全文 长江医药控股股份有限公司 2025 年半年度报告 2025-084 2025 年 8 月 26 日 1 长江医药控股股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人胡士会、主管会计工作负责人杨英环及会计机构负责人(会计 主管人员)杨英环声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 目前，公司已进入预重整阶段，但公司能否进入重整程序存在不确定 性。如果法院裁定受理公司重整申请，根据《深圳证券交易所创业板股票上 市规则》相关规定，公司股票交易将被实施退市风险警示。即使法院正式受 理重整申请，后续仍然存在因重整失败而被宣告破产并被实施破产清算的风 险。如果公司因重整失败而被宣告破产，则根据《深圳证券交易所创业板股 票上市规则》相关规定，公司股票将面临被终止上市的风险。 本报告中如有涉及未来的计划、经营目标、业绩预测等方面的内容，均不 ...

[Key Disclosure Information](index=1&type=section&id=Key%20Disclosure%20Information) The report confirms the board and management's assurance of the quarterly report's accuracy and completeness, noting it remains unaudited - The board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report, free from false records, misleading statements, or major omissions, assuming individual and joint legal responsibility[3](index=3&type=chunk) - The company's principal, chief financial officer, and head of accounting department declare the financial information in the quarterly report is true, accurate, and complete[3](index=3&type=chunk) - This first quarter report is unaudited[4](index=4&type=chunk)[41](index=41&type=chunk) [I. Key Financial Data](index=2&type=section&id=I.%20Key%20Financial%20Data) The company's Q1 2025 financial performance significantly deteriorated, with revenue down **22.50%**, net loss attributable to shareholders widening by **28.01%**, and operating cash flow plummeting by **118.90%**; shareholder equity remained negative and further declined [ (I) Key Accounting Data and Financial Indicators](index=2&type=section&id=%28I%29%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In Q1 2025, revenue and net profit significantly declined, operating cash flow worsened, EPS loss expanded, total assets slightly grew, but shareholder equity remained negative and further decreased Key Accounting Data and Financial Indicators | Indicator | Current Period | Prior Year Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue (RMB) | 45,795,675.76 | 59,091,762.31 | -22.50% | | Net Profit Attributable to Shareholders (RMB) | -60,812,317.13 | -47,505,902.27 | -28.01% | | Net Profit Attributable to Shareholders Excluding Non-recurring Items (RMB) | -62,639,023.43 | -45,659,634.61 | -37.19% | | Net Cash Flow from Operating Activities (RMB) | -71,835,780.49 | -32,816,721.93 | -118.90% | | Basic Earnings Per Share (RMB/share) | -0.1736 | -0.1356 | -28.02% | | Diluted Earnings Per Share (RMB/share) | -0.1736 | -0.1356 | -28.02% | | Weighted Average Return on Net Assets | -13.13% | -27.72% | 14.59% | | **Period-End Indicators** | **Current Period-End** | **Prior Year-End** | **Change from Prior Year-End (%)** | | Total Assets (RMB) | 2,042,496,723.36 | 1,995,717,642.12 | 2.34% | | Shareholders' Equity Attributable to Listed Company (RMB) | -493,652,976.34 | -432,840,659.21 | -14.05% | [ (II) Non-recurring Gains and Losses Items and Amounts](index=2&type=section&id=%28II%29%20Non-recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) Total non-recurring gains and losses for the period amounted to **RMB 1,826,706.30**, primarily from fair value changes in financial assets and debt restructuring, partially offsetting non-current asset disposal losses and non-operating expenses Non-recurring Gains and Losses Items and Amounts | Item | Amount for Current Period (RMB) | Description | | :--- | :--- | :--- | | Gains/Losses on Disposal of Non-current Assets | -101,726.14 | | | Government Grants Included in Current Profit/Loss | 315,367.93 | | | Gains/Losses from Fair Value Changes of Financial Assets and Liabilities Held by Non-financial Enterprises and Disposal of Financial Assets and Liabilities | 2,200,000.00 | | | Debt Restructuring Gains/Losses | 700,000.00 | | | Other Non-operating Income and Expenses Apart from the Above | -224,147.09 | | | Impact on Minority Interests (After Tax) | 1,062,788.40 | | | **Total** | **1,826,706.30** | -- | - The company has not classified any non-recurring gains and losses items listed in 'Interpretive Announcement No. 1 on Information Disclosure by Companies Issuing Securities to the Public—Non-recurring Gains and Losses' as recurring items[7](index=7&type=chunk)[8](index=8&type=chunk) [ (III) Changes and Reasons for Key Accounting Data and Financial Indicators](index=3&type=section&id=%28III%29%20Changes%20and%20Reasons%20for%20Key%20Accounting%20Data%20and%20Financial%20Indicators) Multiple financial indicators saw significant year-over-year changes, including a **52.27%** rise in provisions, **22.50%** revenue decline, **181.54%** surge in financial expenses, **118.90%** deterioration in operating cash flow, and **117.58%** increase in financing cash flow Changes and Reasons for Key Accounting Data and Financial Indicators | Item | Current Period (RMB) | Prior Year Period (RMB) | YoY Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Provisions | 45,808,696.12 | 30,084,303.04 | 52.27% | Due to increase in pending lawsuits | | Operating Revenue | 45,795,675.76 | 59,091,762.31 | -22.50% | Due to year-over-year decrease in pharmaceutical sector revenue | | Operating Cost | 47,500,988.09 | 54,604,638.79 | -13.01% | Due to year-over-year decrease in pharmaceutical sector revenue | | Financial Expenses | 34,973,280.67 | 12,422,196.09 | 181.54% | Due to interest accrued for lawsuits | | Credit Impairment Losses | -31,953,818.21 | -47,021,483.23 | 32.04% | Due to year-over-year decrease in allowance for doubtful accounts | | Non-operating Expenses | 289,356.56 | 3,692,085.55 | -92.16% | Due to compensation expenses arising from product quality issues in the prior year period | | Net Cash Flow from Operating Activities | -71,835,780.49 | -32,816,721.93 | -118.90% | Due to decrease in sales collections | | Net Cash Flow from Financing Activities | 68,545,138.96 | 31,502,907.79 | 117.58% | Due to increase in borrowings | [II. Shareholder Information](index=3&type=section&id=II.%20Shareholder%20Information) As of the reporting period end, the company had **20,224** common shareholders; the top ten shareholders' holdings show Changxing Shengshifenghua Business Co., Ltd. as the largest shareholder with **10.11%**, most of its shares pledged, and the company is unaware of any related party relationships or concerted actions among shareholders [ (I) Total Number of Common Shareholders and Top Ten Shareholders' Holdings](index=3&type=section&id=%28I%29%20Total%20Number%20of%20Common%20Shareholders%20and%20Top%20Ten%20Shareholders%27%20Holdings) At the end of the reporting period, there were **20,224** common shareholders and no preferred shareholders with restored voting rights; among the top ten, Changxing Shengshifenghua Business Co., Ltd. was the largest shareholder with **10.11%**, holding **21,002,800** pledged shares, while Shouguang Kangyue Investment Co., Ltd. had **9,500,000** frozen shares - The total number of common shareholders at the end of the reporting period was **20,224**, and the total number of preferred shareholders with restored voting rights was **0** at the end of the reporting period[12](index=12&type=chunk) Top Ten Common Shareholders' Holdings | Shareholder Name | Shareholder Nature | Holding Ratio (%) | Number of Shares (shares) | Pledged, Marked, or Frozen Status | | :--- | :--- | :--- | :--- | :--- | | Changxing Shengshifenghua Business Co., Ltd. | Domestic Non-state-owned Legal Person | 10.11% | 35,423,600.00 | Pledged 21,002,800.00 | | Shanghai Yucong Asset Management Co., Ltd. - Yucong Tianshun No. 2 Private Securities Investment Fund | Other | 5.99% | 21,000,000.00 | Not Applicable 0.00 | | Liu Lili | Domestic Natural Person | 5.05% | 17,681,253.00 | Not Applicable 0.00 | | Shouguang Kangyue Investment Co., Ltd. | Domestic Non-state-owned Legal Person | 3.46% | 12,114,547.00 | Frozen 9,500,000.00 | | Xu Guifang | Domestic Natural Person | 0.78% | 2,732,600.00 | Not Applicable 0.00 | | Wang Fugen | Domestic Natural Person | 0.70% | 2,461,250.00 | Not Applicable 0.00 | | Li Yufang | Domestic Natural Person | 0.54% | 1,900,005.00 | Not Applicable 0.00 | | Ma Junping | Domestic Natural Person | 0.53% | 1,852,450.00 | Not Applicable 0.00 | | Chen Naping | Domestic Natural Person | 0.52% | 1,836,450.00 | Not Applicable 0.00 | | Hao Kai | Domestic Natural Person | 0.52% | 1,808,050.00 | Not Applicable 0.00 | - The company is unaware of any associated relationships among shareholders or whether they constitute concerted parties as defined by the "Measures for the Administration of the Acquisition of Listed Companies"[13](index=13&type=chunk) - Shareholder Hao Kai holds **800,000** shares through a common securities account and **1,008,050** shares through a Zheshang Securities Co., Ltd. client credit trading guarantee securities account, totaling **1,808,050** shares[13](index=13&type=chunk) [ (II) Preferred Shareholder Information](index=4&type=section&id=%28II%29%20Preferred%20Shareholder%20Information) The company has no preferred shareholders - The company has no preferred shareholders[14](index=14&type=chunk) [ (III) Changes in Restricted Shares](index=4&type=section&id=%28III%29%20Changes%20in%20Restricted%20Shares) There were no changes in the company's restricted shares - There were no changes in the company's restricted shares[14](index=14&type=chunk) [III. Other Significant Matters](index=4&type=section&id=III.%20Other%20Significant%20Matters) The company faces severe going concern uncertainties, including negative net assets, huge accumulated losses, significant revenue decline, numerous overdue debts, and frozen bank accounts; additionally, the company has entered pre-reorganization, its subsidiaries have been ruled for bankruptcy reorganization, posing significant risks of reorganization failure and stock delisting [ (I) Risk Warning for Significant Uncertainties Related to Going Concern in the 2024 Annual Audit Report](index=4&type=section&id=%28I%292024%20Annual%20Audit%20Report%20Risk%20Warning%20for%20Significant%20Uncertainties%20Related%20to%20Going%20Concern) As of year-end 2024, the company had negative net assets, substantial accumulated losses, three consecutive years of negative operating cash flow, and severe revenue decline; numerous overdue debts led to frozen bank accounts and seized assets, with subsidiaries entering bankruptcy reorganization, indicating significant going concern uncertainties - As of December 31, 2024, the company's consolidated financial statements showed net assets attributable to the parent company of **-RMB 432,840,659.21**, undistributed profits of **-RMB 1,589,707,417.48**, and net profit attributable to parent company shareholders of **-RMB 627,961,728.50** for 2024[14](index=14&type=chunk) - The company's net operating cash flow has been negative for **3** consecutive years, with a huge accumulated loss[14](index=14&type=chunk) - The company's operating revenue has severely declined from **RMB 1.615 billion** in 2022 and **RMB 1.198 billion** in 2023 to **RMB 112 million** in 2024[14](index=14&type=chunk) - Numerous overdue debts have led to lawsuits from some creditors, resulting in a large number of frozen bank accounts and seized assets[14](index=14&type=chunk) - On January 20, 2025, the Shiyan Intermediate People's Court of Hubei Province decided to initiate pre-reorganization for Changyao Holdings; on March 10, 2025, the Shiyan Intermediate People's Court ruled for the bankruptcy reorganization of subsidiary Hubei Changjiang Star Pharmaceutical Co., Ltd.; on March 27, 2025, the Shiyan Intermediate People's Court ruled for the consolidated reorganization of seven subsidiaries[15](index=15&type=chunk) - The aforementioned matters or circumstances indicate significant uncertainties regarding Changyao Holdings' ability to continue as a going concern without major changes[16](index=16&type=chunk) [ (II) Risk of Reorganization Failure](index=4&type=section&id=%28II%29%20Risk%20of%20Reorganization%20Failure) The company has entered pre-reorganization, but its formal entry into reorganization remains uncertain; if the court accepts the reorganization application, the company's stock will be subject to delisting risk warnings, and if reorganization fails, the company may be declared bankrupt and liquidated, facing the risk of stock delisting - The company entered the pre-reorganization phase on January 20, 2025, but whether it can formally enter the reorganization process remains uncertain[18](index=18&type=chunk) - If the court rules to accept the company's reorganization application, the company's stock trading will be subject to delisting risk warnings[18](index=18&type=chunk) - Even if the court formally accepts the reorganization application, there is still a risk of being declared bankrupt and liquidated due to reorganization failure, which may lead to the company's stock facing the risk of delisting[18](index=18&type=chunk) [ (III) Risk of Stock Delisting](index=5&type=section&id=%28III%29%20Risk%20of%20Stock%20Delisting) The company's stock has been subject to delisting risk warnings since April 22, 2025; according to the "Shenzhen Stock Exchange ChiNext Stock Listing Rules," if the company's 2025 audited total profit, net profit, or net profit after non-recurring items is negative and operating revenue after deduction is below **RMB 100 million**, or if net assets at year-end are negative, or if the financial report receives a non-standard audit opinion, the company's stock will face delisting risk - The company's stock trading has been subject to delisting risk warnings since April 22, 2025[19](index=19&type=chunk) - If the company's 2025 audited total profit, net profit, or net profit after deducting non-recurring gains and losses is negative, and the operating revenue after deduction is below **RMB 100 million**, the Shenzhen Stock Exchange will decide to terminate the company's stock listing[19](index=19&type=chunk)[27](index=27&type=chunk) - If the company's 2025 audited net assets at year-end are negative, the Shenzhen Stock Exchange will decide to terminate the company's stock listing[20](index=20&type=chunk)[27](index=27&type=chunk) - If the company's 2025 financial accounting report receives a qualified, adverse, or disclaimer of opinion audit report, the Shenzhen Stock Exchange will decide to terminate the company's stock listing[21](index=21&type=chunk)[27](index=27&type=chunk) - Investors are kindly requested to pay attention to investment risks[28](index=28&type=chunk) [IV. Quarterly Financial Statements](index=5&type=section&id=IV.%20Quarterly%20Financial%20Statements) This section provides the company's consolidated balance sheet, consolidated income statement, and consolidated cash flow statement for Q1 2025, detailing the financial position, operating results, and cash flows at the end of the reporting period; the company did not adopt new accounting standards for the first time in this period, and the quarterly report is unaudited [ (I) Financial Statements](index=5&type=section&id=%28I%29%20Financial%20Statements) Includes the consolidated balance sheet, consolidated income statement, and consolidated cash flow statement, reflecting the company's assets, liabilities, owner's equity, revenue, expenses, profit, and cash inflows and outflows for Q1 2025 [1. Consolidated Balance Sheet](index=5&type=section&id=1.%20Consolidated%20Balance%20Sheet) As of March 31, 2025, the company's total assets were **RMB 2.042 billion**, a **2.34%** increase from the beginning of the period; total current assets were **RMB 1.185 billion**, and total non-current assets were **RMB 858 million**; total liabilities were **RMB 2.553 billion**, with current liabilities at **RMB 2.045 billion** and non-current liabilities at **RMB 508 million**; owner's equity attributable to the parent company was **-RMB 494 million**, minority interests were **-RMB 17 million**, and total owner's equity was **-RMB 511 million**, indicating persistently negative net assets Consolidated Balance Sheet | Item | Period-End Balance (RMB) | Period-Beginning Balance (RMB) | | :--- | :--- | :--- | | **Assets** | | | | Total Current Assets | 1,184,629,835.39 | 1,129,357,419.11 | | Total Non-current Assets | 857,866,887.97 | 866,360,223.01 | | **Total Assets** | **2,042,496,723.36** | **1,995,717,642.12** | | **Liabilities** | | | | Total Current Liabilities | 2,045,192,800.38 | 1,924,644,829.41 | | Total Non-current Liabilities | 508,055,500.27 | 492,427,835.02 | | **Total Liabilities** | **2,553,248,300.65** | **2,417,072,664.43** | | **Owner's Equity** | | | | Total Owner's Equity Attributable to Parent Company | -493,652,976.34 | -432,840,659.21 | | Minority Interests | -17,098,600.95 | 11,485,636.90 | | **Total Owner's Equity** | **-510,751,577.29** | **-421,355,022.31** | - Cash and cash equivalents at period-end amounted to **RMB 9,012,776.10**, while accounts receivable reached **RMB 1,023,063,349.86**[30](index=30&type=chunk)[31](index=31&type=chunk) - Other payables amounted to **RMB 1,324,188,274.25**, including interest payable of **RMB 12,738,377.66**[32](index=32&type=chunk) - Undistributed profits were **-RMB 1,650,519,734.61**, further deteriorating from the beginning of the period[32](index=32&type=chunk) [2. Consolidated Income Statement](index=7&type=section&id=2.%20Consolidated%20Income%20Statement) In Q1 2025, the company's total operating revenue was **RMB 45.80 million**, a **22.50%** year-over-year decrease; total operating costs were **RMB 106 million**, with financial expenses significantly increasing by **181.54%** year-over-year; the company reported a net loss of **RMB 89.40 million**, and net loss attributable to parent company owners was **RMB 60.81 million**, widening the loss compared to the prior year period Consolidated Income Statement | Item | Amount for Current Period (RMB) | Amount for Prior Period (RMB) | | :--- | :--- | :--- | | Total Operating Revenue | 45,795,675.76 | 59,091,762.31 | | Total Operating Costs | 106,127,907.23 | 89,749,307.79 | | Including: Operating Cost | 47,500,988.09 | 54,604,638.79 | | Selling Expenses | 2,939,791.68 | 5,103,682.48 | | Administrative Expenses | 19,053,546.04 | 16,085,180.97 | | Financial Expenses | 34,973,280.67 | 12,422,196.09 | | Credit Impairment Losses | -31,953,818.21 | -47,021,483.23 | | Operating Profit | -89,172,407.89 | -77,433,335.93 | | Total Profit | -89,396,554.98 | -81,120,269.42 | | Net Profit | -89,396,554.98 | -81,120,269.42 | | Net Profit Attributable to Parent Company Owners | -60,812,317.13 | -47,505,902.27 | | Basic Earnings Per Share | -0.1736 | -0.1356 | - Investment income for the current period was **RMB 2,900,000.00**, compared to **RMB 0** in the prior period[35](index=35&type=chunk) - Minority interest loss was **-RMB 28,584,237.85**, an improvement from **-RMB 33,614,367.15** in the prior period[36](index=36&type=chunk) [3. Consolidated Cash Flow Statement](index=9&type=section&id=3.%20Consolidated%20Cash%20Flow%20Statement) In Q1 2025, net cash flow from operating activities was **-RMB 71.84 million**, a **118.90%** year-over-year deterioration primarily due to reduced sales collections; net cash flow from investing activities turned positive to **RMB 1.17 million**, mainly from other cash received related to investing activities; net cash flow from financing activities was **RMB 68.55 million**, a **117.58%** year-over-year increase primarily due to increased borrowings; cash and cash equivalents balance at period-end was **RMB 3.29 million** Consolidated Cash Flow Statement | Item | Amount for Current Period (RMB) | Amount for Prior Period (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -71,835,780.49 | -32,816,721.93 | | Net Cash Flow from Investing Activities | 1,174,560.80 | -2,690,657.00 | | Net Cash Flow from Financing Activities | 68,545,138.96 | 31,502,907.79 | | Net Increase in Cash and Cash Equivalents | -2,116,098.55 | -3,984,366.60 | | Cash and Cash Equivalents at Period-End | 3,289,786.32 | 2,316,745.24 | - Cash received from sales of goods and rendering of services for the current period was **RMB 39,130,032.28**, a year-over-year decrease of approximately **20.8%** from **RMB 49,400,392.01** in the prior period[38](index=38&type=chunk) - Cash paid for goods and services for the current period was **RMB 88,612,091.37**, a year-over-year increase of approximately **50.8%** from **RMB 58,777,551.13** in the prior period[39](index=39&type=chunk) - Other cash received related to investing activities was **RMB 1,320,000.00** for the current period, compared to **RMB 0** in the prior period[39](index=39&type=chunk) - Cash paid for debt repayment for the current period was **RMB 288,981.79**, a significant decrease from **RMB 16,548,619.51** in the prior period[40](index=40&type=chunk) [ (II) Adjustments for First-time Adoption of New Accounting Standards in 2025](index=11&type=section&id=%28II%29%20Adjustments%20for%20First-time%20Adoption%20of%20New%20Accounting%20Standards%20in%202025) The company did not adopt new accounting standards for the first time in 2025, thus no adjustments to the opening financial statements for the first year of adoption are required - The company did not adopt new accounting standards for the first time in 2025[41](index=41&type=chunk) [ (III) Audit Report](index=11&type=section&id=%28III%29%20Audit%20Report) The company's Q1 2025 report is unaudited - The company's first quarter report is unaudited[41](index=41&type=chunk)

2、本次会计差错更正事项仅对公司2025年第一季度报告中合并利润表的相关 项目及指标有影响。 公司于2025年8月22日召开第六届董事会第二次会议，审议通过了《关于2025 年第一季度财务报告会计差错更正的议案》，同意公司按照《企业会计准则第28 号——会计政策、会计估计变更和差错更正》《公开发行证券的公司信息披露编报 规则第19号——财务信息的更正及相关披露》的相关规定和要求，对相关会计差错 进行更正。公司本次会计差错更正仅涉及2025年第一季度合并利润表，具体情况如 下： 一、会计差错更正情况 证券代码：300391 证券简称：*ST 长药 公告编号：2025-080 长江医药控股股份有限公司 关于2025年第一季度财务报告会计差错更正的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 特别提示： 1、本次会计差错更正影响长江医药控股股份有限公司（以下简称"公司"） 2025年度第一季度合并利润表营业收入、营业总收入、营业成本、营业总成本，不 影响2025年第一季度合并资产负债表、合并现金流量表。 《企业会计准则第14号——收入》第三十四条："企业应当 ...

Core Insights - The article highlights the development of the power equipment industry in Weifang, Shandong, emphasizing its significant scale and structural advantages, aiming to become a world-class industrial cluster [3][12]. Group 1: Industry Scale and Structure - Weifang has a "national-level" power equipment cluster with an annual output value of 300 billion yuan, accounting for one-third of the national power equipment industry total [3]. - The region has formed a closely-knit network of supporting enterprises around leading companies like Weichai, ensuring local suppliers are available for nearly every aspect of the power equipment sector [3]. Group 2: Collaborative Ecosystem - The long supply chain and comprehensive support in Weifang foster tight cooperation among large, medium, and small enterprises, with larger companies driving industry chain development and smaller firms focusing on niche markets [4][5]. - Weichai plays a pivotal role as a "big brother" in the ecosystem, leveraging its technological capabilities and industry collaboration to create a unique industrial ecosystem [5]. Group 3: Role of Small and Medium Enterprises - Small and medium enterprises (SMEs) in Weifang focus on key segments of the industry chain, engaging in specialized fields and competing in a complementary manner with larger firms [6][7]. - Weifang ranks first in Shandong for the number of specialized and innovative enterprises, supported by a strong industrial foundation and clear business positioning [7]. Group 4: Education and Talent Development - Weifang addresses the common issue of skilled labor shortages in manufacturing through effective industry-education integration, ensuring a steady supply of skilled workers [10][11]. - The local government promotes collaboration between large enterprises and vocational schools to meet the workforce needs of SMEs, enhancing the overall talent pool [11]. Group 5: Innovation and Future Directions - The industry ecosystem in Weifang is moving towards high-end, intelligent, and green development, with companies investing in advanced technologies and sustainable practices [12][16]. - Intelligent manufacturing is becoming essential, with companies like Foton Motor implementing automation to significantly improve labor efficiency and reduce costs [15]. - Green transformation is supported by local policies and market demand, with companies innovating in materials and processes to meet environmental standards [16].

Group 1: Industry Overview - Shandong Weifang has a significant presence in the power equipment sector, with an annual output value of 300 billion yuan, accounting for one-third of the national total in this industry [1] - The region has developed a close-knit ecosystem of supporting enterprises around leading companies like Weichai, enabling local suppliers to cover nearly all aspects of the power equipment supply chain [1] Group 2: Collaborative Ecosystem - The collaboration among large, medium, and small enterprises in Weifang is increasingly tight, with large companies driving industry chain development while smaller firms focus on niche markets [2] - Weichai serves as a key player, linking upstream and downstream enterprises to foster a unique industrial ecosystem that emphasizes growth and collaboration rather than zero-sum competition [3] Group 3: Role of Large Enterprises - Large enterprises are expected to be ecosystem anchors and linkers, with Weichai exemplifying this through its high thermal efficiency of 53.09%, which can save 12,000 liters of diesel per heavy truck annually [3] - Other notable large companies include GoerTek and Haomai Group, which also play significant roles in supporting smaller firms and integrating them into the supply chain [3] Group 4: Role of Small Enterprises - Small and medium-sized enterprises (SMEs) focus on critical segments of the industry chain, with examples like Kangyue Technology leading in turbocharging technology, which is vital for fuel efficiency in traditional vehicles [4] - Weifang ranks first in Shandong for the number of specialized and innovative enterprises, showcasing its strong industrial foundation and clear business positioning [4] Group 5: Education and Talent Development - Weifang has effectively addressed the skills shortage in manufacturing through a strong integration of education and industry, with vocational training closely aligned with real production needs [7][8] - The local government supports this integration by facilitating partnerships between large enterprises and vocational schools, ensuring a steady supply of skilled labor [9] Group 6: Industrial Ecosystem and Future Directions - The region is moving towards high-end, intelligent, and green manufacturing, with companies like Ruou Intelligent Manufacturing focusing on high-value products and North Benz Foton implementing smart manufacturing strategies [10][12] - Green transformation is supported by local policies and market demand, with companies investing in new materials and technologies to meet environmental standards [13][14]

证券代码：300391 证券简称：*ST长药 公告编号：2025-078 长江医药控股股份有限公司 重大诉讼的进展公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 重要内容提示： 原告财通证券股份有限公司与被告长江医药控股股份有限公司、第三人湖北 长江大药房连锁有限公司债权人代位权纠纷案，十堰市郧阳区人民法院于2025年 4月10日立案。在诉讼过程中财通证券股份有限公司向十堰市郧阳区人民法院申 请财产保全，法院裁定冻结长江医药控股股份有限公司银行存款50,546,191.97 元或查封、扣押、冻结其同等价值的其他财产。本案涉案金额50,566,410.45元， 预计不会对公司当期损益产生影响。 一、诉讼事项受理的基本情况 2025年8月4日，长江医药控股股份有限公司（以下简称"公司"、"长药控 股"）收到十堰市郧阳区人民法院送达的民事裁定书。十堰市郧阳区人民法院所 在地为湖北省十堰市郧阳区沿江大道26号。财通证券股份有限公司债权人代位权 纠纷案的诉讼各方当事人如下： 财通证券股份有限公司债权人代位权纠纷案的基本情况，详见公司于2025年 4月17日披露于巨潮 ...

Group 1 - The core point of the article is that *ST Changyao has announced that as of the disclosure date, shareholder Shengshi Fenghua has had approximately 8.1 million shares frozen [2] - For the fiscal year 2024, *ST Changyao's revenue composition is as follows: 57.19% from the photovoltaic industry and 42.81% from the pharmaceutical industry [2]

证券代码：300391 证券简称：*ST长药 公告编号：2025-077 长江医药控股股份有限公司 关于控股股东部分股份冻结的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 长江医药控股股份有限公司（以下简称"公司"、"长药控股"或"上市公 司"）近日接到控股股东长兴盛世丰华商务有限公司（以下简称"盛世丰华"） 的通知，盛世丰华持有的公司部分股份被冻结，具体事项如下： 一、股东股份被冻结的基本情况 | 股东 名称 | 是否为控股股东 或第一大股东及 | 本次冻结/标 记/拍卖等股 | 占其所持 | 占公司总 | 是否为限 售股及限 | | | 起始日 到期日 | | 冻结申请人 /拍卖人等 | 原因 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 股份比例 | 股本比例 | | | | | | | | | | 其一致行动人 | 份数量（股） | | | 售类型 | | | | | | | | 盛世 | 是 | 8,101,700 | 22 ...